LeonaBio

LeonaBio Equity

The The Equity of LeonaBio (LONA) as of Oct 22, 2026 is 27.79 M USD. In the previous year, The Equity was 44.84 M USD — a change of -38.03% (lower).

Equity

27.79 MUSD

YoY

-38.03%

Last updated:

In 2025, LeonaBio's equity was 27.79 M USD, a -38.03% increase from the 44.84 M USD equity in the previous year.

The LeonaBio Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
-14.89 M USD
Jan 1, 2019
-19.72 M USD
Jan 1, 2020
274.28 M USD
Jan 1, 2021
321.08 M USD
Jan 1, 2022
235.14 M USD
Jan 1, 2023
130.19 M USD
Jan 1, 2024
44.84 M USD
Jan 1, 2025
27.79 M USD
The LeonaBio Equity history
YEAREquityYoY
27.79 MUSD-38.03%
44.84 MUSD-65.56%
130.19 MUSD-44.63%
235.14 MUSD-26.77%
321.08 MUSD+17.06%
274.28 MUSD-1,490.67%
-19.72 MUSD+32.48%
-14.89 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LeonaBio Stock analysis

What does LeonaBio do? Athira Pharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Bothell, Washington, that generates revenue by developing small molecules to restore neuronal health and stop neurodegeneration. The firm utilizes its proprietary ATH platform to target and enhance the activity of a vital neuronal growth factor, creating a pipeline of drugs designed to cross the blood brain barrier for the central nervous system or target the peripheral nervous system. This technology underpins the development of ATH-1017, which is specifically intended for the treatment of neurodegenerative disorders with an initial focus on Alzheimer’s disease. The product aims to improve symptoms in cognitively impaired subjects by enhancing neuronal health and promoting regeneration, serving the medical needs of patients suffering from these conditions. LeonaBio is one of the most popular companies on Eulerpool.

Equity Details

Analyzing LeonaBio's Equity

LeonaBio's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding LeonaBio's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating LeonaBio's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

LeonaBio's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in LeonaBio’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about LeonaBio stock

The Equity of LeonaBio is 27.79 M USD in 2025.

The Equity of LeonaBio changed from 44.84 M USD to 27.79 M USD, representing a -38.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity LeonaBio since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's LeonaBio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — LeonaBio

All Key Metrics — LeonaBio